BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Healthtrust Education - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Healthtrust Education
X-ORIGINAL-URL:https://education.healthtrustpg.com
X-WR-CALDESC:Events for Healthtrust Education
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20240529T120000
DTEND;TZID=America/Chicago:20240529T130000
DTSTAMP:20260617T082420
CREATED:20240415T213326Z
LAST-MODIFIED:20250311T203624Z
UID:10003634-1716984000-1716987600@education.healthtrustpg.com
SUMMARY:"Present Use & Future Directions of Bispecific Molecules in Relapsed or Refractory Multiple Myeloma"
DESCRIPTION:HealthTrust presents…“Present Use & Future Directions of Bispecific Molecules in Relapsed or Refractory Multiple Myeloma” \n \nDownload the content. \nPlease Note: Continuing education credit is only available to those attending the session live. CE credit is not available when accessing the program on demand. \nMultiple myeloma is a malignant neoplasm of plasma cells in the blood that accumulate in the bone marrow\, leading to blood dyscrasias\, bone damage\, infections\, and renal damage. Due to the incurable nature of the malignancy\, patients may undergo several lines of treatment. Multiple myeloma remains incurable\, therefore\, the development of additional options for relapsed or refractory disease is vital. Approved therapies have shown success targeting B-cell maturation antigen (BCMA); however\, additional targets are being explored in clinical trials. Due to the evolving nature of oncology\, pharmacists are consistently introduced to new therapies and thus should be familiar with those in development. This session will focus on current FDA-approved bispecific molecules\, differentiating between bispecific antibodies and bispecific T-cell engagers\, toxicities associated with these therapies\, and current NCCN guideline recommendations. Ongoing clinical trials and advances in bispecific research will also be provided to highlight the evolving future of these agents. \nLearning Objectives for Pharmacists & Nurses  |  At the end of this session\, participants should be able to: \n\nRecall the current landscape of bispecific molecule treatment of relapsed or refractory multiple myeloma\nIdentify the differences between current FDA approved bispecific antibodies and bispecific T-cell engagers\nRecognize treatment strategies currently being utilized in bispecific molecule clinical trials\n\nPresenter: \n \nBrielle Stawicki\, PharmD  |  PGY-1 Resident  |  Atlantic Health System \nTarget Audience: Pharmacists\, Nurses &  Physicians \nCE Credit: Approved for Pharmacists & Nurses \nThis program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this activity is 0863-9999-24-069-L01-P. The activity is approved for Pharmacists and Nurses for 1 hour (.1 CEUs) of continuing education credit for those who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN\, provider approved by the California Board of Registered Nursing\, Provider Number CEP13019\, for 1 contact hour. 1.0 contact hours approved for Nurses. \nNote about CE credit: If you plan to obtain credit for a live session\, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone\, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.
URL:https://education.healthtrustpg.com/calendar/present-use-and-future-directions-of-bispecific-molecules-in-relapsed-or-refractory-multiple-myeloma/
CATEGORIES:Nursing,Pharmacy,Physicians
END:VEVENT
END:VCALENDAR